GlassScriptPhysician profile
Archana Jarathi
NPI 1487801056
$7,262.56
in general payments reported to CMS, 2019-2025
37 companies · $705 in 2025
The $705 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,833 · 2020: $872 · 2021: $928 · 2022: $1,387 · 2023: $747 · 2024: $790 · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,242.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $716.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $680.19 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $674.85 | 2019-2025 | |
| Lilly USA, LLC | $673.54 | 2019-2025 | Jardiance, Mounjaro, Lyumjev |
| Dexcom, INC. | $601.69 | 2019-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $497.08 | 2020-2025 | Jardiance |
| Amgen INC. | $423.77 | 2019-2024 | Tepezza, Repatha |
| Insulet Corporation | $334.58 | 2019-2025 | Omnipod |
| Abbvie INC. | $327.82 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $308.18 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $284.16 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $263.65 | 2021-2024 | Gvoke Hypopen, Recorlev |
| Astrazeneca Pharmaceuticals LP | $253.68 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $209.49 | 2019-2020 | |
| Corcept Therapeutics | $169.55 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $94.82 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Nevro Corp. | $82.04 | 2024 | Senza |
| Neurocrine Biosciences, INC. | $62.63 | 2024-2025 | |
| Valeritas, INC. | $61.71 | 2019 | |
| Acella Pharmaceuticals, LLC | $56.71 | 2024-2025 | NP Thyroid 60 |
| Beta Bionics, INC. | $55.96 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Regeneron Healthcare Solutions, INC. | $47.84 | 2019 | |
| Medtronic, INC. | $47.53 | 2021-2022 | |
| Pfizer INC. | $47.10 | 2019-2021 | |
| Recordati_rare_diseases_inc. | $45.98 | 2021-2022 | |
| Cequr Corporation | $34.12 | 2025 | Cequr Simplicity |
| Esperion Therapeutics, INC. | $25.82 | 2020-2021 | |
| Eusa Pharma (US) LLC | $25.03 | 2022 | |
| Averitas Pharma INC. | $24.76 | 2025 | Qutenza |
| Ibsa Pharma INC. | $20.34 | 2024 | Tirosint, Licart |
| Kyowa Kirin, INC. | $20.28 | 2024 | Crysvita |
| Ipsen Biopharmaceuticals, INC | $18.57 | 2019 | |
| Ascensia Diabetes Care US INC. | $18.54 | 2025 | |
| Zealand Pharma US, INC. | $16.29 | 2021 | |
| Ascendis Pharma Endocrinology INC | $13.65 | 2025 | Yorvipath |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.08 | 2019 | |
| Lifescan, INC. | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archana Jarathi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.